Topical Losartan Treatment of Herpes Simplex Virus- or Varicella-Zoster Virus-Induced Corneal Scarring: A Case Series.

ABSTRACT:

Introduction

Topical losartan has emerged as a promising therapeutic option for preventing and treating corneal scarring fibrosis. Its mechanism of action involves the inhibition of ERK-mediated signaling in the noncanonical TGF-beta pathways, promoting apoptosis of myofibroblasts and facilitating a return of corneal transparency. While numerous studies in rabbits and several human case reports have demonstrated its efficacy and safety, published data on its use in clinical scenarios remain limited. This study presents 3 cases where topical losartan successfully treated corneal scarring induced by herpes simplex virus (HSV) or varicella-zoster virus (VZV) keratitis.

Case presentations

Three patients (ages 40, 38, 15 years) with corneal scarring and vision loss from HSV or VZ

SUBMITTER: Dutra BAL 

PROVIDER: S-EPMC12005691 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature